title: Onychomycosis: Strategies to Minimize Recurrence.
abstract: Recurrence (relapse or re-infection) in onychomycosis is common, occurring in 10% to 53% of patients. However, data on prevalence is limited as few clinical studies follow patients beyond 12 months. It has been suggested that recurrence after continuous terbinafine treatment may be less common than with intermittent or continuous itraconazole therapy, probably due to the fungicidal activity of terbinafine, although these differences tended not to be significant. Relapse rates also increase with time, peaking at month 36. Although a number of factors have been suggested to play a role in recurrence, only the co-existence of diabetes has been shown to have a significant impact. Data with topical therapy is sparse; a small study showed amorolfine prophylaxis may delay recurrence. High concentrations of efinaconazole have been reported in the nail two weeks' post-treatment suggesting twice monthly prophylaxis with topical treatments may be a realistic option, and may be an important consideration in diabetic patients with onychomycosis. Data suggest that prophylaxis may need to be continued for up to three years for optimal effect. Treating tinea pedis and any immediate family members is also critical. Other preventative strategies include avoiding communal areas where infection can spread (such as swimming pools), and decontaminating footwear.
authors.forename: Aditya K
authors.initials: AK
authors.lastname: Gupta
authors.forename: Boni E
authors.initials: BE
authors.lastname: Elewski
authors.forename: Ted
authors.initials: T
authors.lastname: Rosen
authors.forename: Bryan
authors.initials: B
authors.lastname: Caldwell
authors.forename: David M
authors.initials: DM
authors.lastname: Pariser
authors.forename: Leon H
authors.initials: LH
authors.lastname: Kircik
authors.forename: Neal
authors.initials: N
authors.lastname: Bhatia
authors.forename: Antonella
authors.initials: A
authors.lastname: Tosti
mesh_terms: D000287:Administration, Topical; D000935:Antifungal Agents / Q000008:administration & dosage / Q000032:analysis / Q000627:therapeutic use*; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000453:epidemiology; D004334:Drug Administration Schedule; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D009025:Morpholines / Q000627:therapeutic use*; D009281:Naphthalenes / Q000008:administration & dosage / Q000627:therapeutic use*; D014009:Onychomycosis / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D015995:Prevalence; D012008:Recurrence; D000077291:Terbinafine; D014008:Tinea Pedis / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D014230:Triazoles / Q000008:administration & dosage / Q000032:analysis / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D009025:Morpholines; D009281:Naphthalenes; D014230:Triazoles; D017964:Itraconazole; C038974:amorolfine; D000077291:Terbinafine; C431707:efinaconazole